Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Wald

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Transplantation and Cellular Therapy|February 16, 2022
A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult DonorsFolashade Otegbeye, Brenda Cooper, Paolo Caimi, et al.
Immunity|April 3, 2007
The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesisHui Xiao, Muhammet Fatih Gulen, Jinzhong Qin, et al.
Frontiers in Immunology|February 5, 2026
Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024Gisela Maria Suárez Formigo, Zaima Mazorra, Cinthia Olexen, et al.
Haematologica|November 7, 2024
Arsenic trioxide <i>versus</i> Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trialShu Chen, Weiwei Qin, Xiaohong Lu, et al.
Molecular Cancer|May 28, 2026
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemiaShakti P Pattanayak, Odai Darawshi, Omid Hajihassani, et al.
Research Square|May 4, 2026
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemiaShakti P Pattanayak, Odai Darawshi, Omid Hajihassani, et al.
The Journal of Clinical Investigation|July 18, 2018
Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fatesXiaorong Gu, Quteba Ebrahem, Reda Z Mahfouz, et al.
Haematologica|May 9, 2024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapyChiara Tarantelli, David Wald, Nicolas Munz, et al.
Transplantation and Cellular Therapy|July 10, 2024
An Extended Flow Cytometry Evaluation of ex Vivo Expanded NK Cells Using K562.Clone1, a Feeder Cell Line Manufactured in BrazilCaroline Mitiká Watanabe, Caroline Ishihama Suzuki, Alessandro Marins Dos Santos, et al.
Nature Communications|December 11, 2021
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patientsMichael Maschan, Paolo F Caimi, Jane Reese-Koc, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Transplantation and Cellular Therapy|February 16, 2022
A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult DonorsFolashade Otegbeye, Brenda Cooper, Paolo Caimi, et al.
Immunity|April 3, 2007
The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesisHui Xiao, Muhammet Fatih Gulen, Jinzhong Qin, et al.
Frontiers in Immunology|February 5, 2026
Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024Gisela Maria Suárez Formigo, Zaima Mazorra, Cinthia Olexen, et al.
Haematologica|November 7, 2024
Arsenic trioxide <i>versus</i> Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trialShu Chen, Weiwei Qin, Xiaohong Lu, et al.
Molecular Cancer|May 28, 2026
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemiaShakti P Pattanayak, Odai Darawshi, Omid Hajihassani, et al.
Research Square|May 4, 2026
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemiaShakti P Pattanayak, Odai Darawshi, Omid Hajihassani, et al.
The Journal of Clinical Investigation|July 18, 2018
Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fatesXiaorong Gu, Quteba Ebrahem, Reda Z Mahfouz, et al.
Haematologica|May 9, 2024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapyChiara Tarantelli, David Wald, Nicolas Munz, et al.
Transplantation and Cellular Therapy|July 10, 2024
An Extended Flow Cytometry Evaluation of ex Vivo Expanded NK Cells Using K562.Clone1, a Feeder Cell Line Manufactured in BrazilCaroline Mitiká Watanabe, Caroline Ishihama Suzuki, Alessandro Marins Dos Santos, et al.
Nature Communications|December 11, 2021
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patientsMichael Maschan, Paolo F Caimi, Jane Reese-Koc, et al.
Pageof 6